Shots:

• The NMPA has approved an IND application to initiate the P-I (PROBE-CN), dose-escalation, and a dose-expansion study to evaluate the safety and tolerability of ATG-101 (IV) in patients with advanced/ metastatic solid tumors and B-NHL
• In preclinical studies, the therapy showed significant anti-tumor activity in animal models of resistant tumors along with the patients on anti-PD-1/L1 treatment. The therapy demonstrated an excellent safety profile in GLP toxicology studies
• ATG-101 is a PD-L1/4-1BB bi-specific Ab that was designed to activate anti-tumor immune effectors by forming a cell-Ab-cell trimer to block the binding of PD-L1/PD-1 & induce 4-1BB stimulation

Ref: PR Newswire | Image: Antengene